Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6465472 | 0.88 | HPGD (0.38) | HPGDGAACNR1CNR2KDM4E | |
| SCHEMBL17825593 | 0.81 | KDM4E (0.38) | HPGDGAACNR1CNR2KDM4E | |
| SCHEMBL9068005 | 0.79 | L3MBTL1 (0.37) | KDM4EKMT2AATMSMN1; SMN2HTT | |
| SCHEMBL9261650 | 0.79 | TAS1R3 (0.36) | CNR1CNR2KMT2ASMN1; SMN2HTT | |
| SCHEMBL8842917 | 0.77 | HPGD (0.39) | HPGDGAAKDM4EPOLBKMT2A | |
| SCHEMBL8843149 | 0.77 | KMT2A (0.40) | HPGDGAAKDM4EPOLBKMT2A | |
| SCHEMBL8843206 | 0.77 | HPGD (0.39) | HPGDGAAKDM4EPOLBKMT2A | |
| SCHEMBL8734436 | 0.75 | SMN1; SMN2 (0.35) | CNR1CNR2KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL5023010 | 0.74 | CHRM2 (0.36) | CNR1CNR2SMN1; SMN2TAAR1 | |
| SCHEMBL8457737 | 0.74 | KMT2A (0.42) | GAAKDM4EKMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050009041-A1 | Peptide nucleic acids and synthetic procedures therefor | BUCHARDT OLE (DK) | 2005-01-13 | — | — | US | disclosed |
| US-6713602-B1 | COMPOUNDS THAT ARE NOT POLYNUCLEOTIDES YET WHICH BIND TO COMPLEMENTARY DNA AND RNA STRANDS MORE STRONGLY THE CORRESPONDING DNA | BUCHARDT OLE (DK) | 2004-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009041-A1 | Peptide nucleic acids and synthetic procedures therefor | POLRMT, CPSF7, RNGTT | HPGD 4345/4885GAA 1440/4885CNR1 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.